Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

2 results

  • 11 - Biomarkers for Alzheimer’s Disease

  • Daniel Gibbs, Emeritus of Oregon Health and Science University
  • Book:
    Dispatches from the Land of Alzheimer's
    Published online:
    19 January 2024
    Print publication:
    22 February 2024, pp 49-51

  • Summary

    Brain imaging tests such as CT and MRI scans can be helpful biomarkers for frontotemporal dementia because of the typical atrophy of the frontal and temporal lobes sparing more posterior parts of the brain. For other types of dementia, these imaging tests are not as helpful, although they may be important to rule out tumors, strokes, and hydrocephalus (excess fluid in the brain). Over the last ten years or so, PET scans that can image beta-amyloid plaques and tau-containing tangles have been developed and are now clinically available. These scans can be very useful in confirming a diagnosis of Alzheimer’s and staging the severity of the disease in research settings. However, they are very expensive and often not covered by insurance, presenting barriers for clinical use outside of research.